In addition to the risk that children with CPP will not reach their adult height potential, a range of studies have noted a high risk for psychological, social, and behavioral problems in this population.
Endocrine events that signal less exposure to estradiol, such as shorter reproductive span, younger age at menopause, and hysterectomy, increase dementia risk.
TherapeuticsMD announced the launch of Bijuva (estradiol and progesterone) capsules for use in women with a uterus for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause.
In pregnant women with polycystic ovary syndrome (PCOS), metformin treatment from the late first trimester until delivery might reduce the risk for late miscarriage and preterm birth but does not prevent gestational diabetes.
Researchers have identified reproductive risk factors associated with an increased risk for total knee replacement in women with severe knee osteoarthritis.
In a subanalysis, researchers discovered that testosterone deficiency was common in men with a sustained virologic response after being treated for hepatitis C.
Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.
The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
Women who become pregnant from infertility treatment may be at an increased risk for postpartum hemorrhage, admission to the intensive care unit, or puerperal sepsis as well as death.
